News >

PROSTVAC Misses Phase III Goal in Prostate Cancer

Silas Inman @silasinman
Published: Friday, Sep 15, 2017

Paul Chaplin
Paul Chaplin
The PSA-targeted immunotherapy PROSTVAC was deemed unlikely to demonstrate an improvement in overall survival (OS) compared with placebo for patients with metastatic castration-resistant prostate cancer (CRPC), according to a preplanned interim analysis of the phase III PROSPECT trial conducted by an independent Data Monitoring Committee (DMCB).

The ongoing phase II study exploring PROSTVAC with ipilimumab plans to recruit 75 participants. The estimated completion date for the study is December 2020, with a primary endpoint focused on immune response. The phase I/II study of PROSTVAC with nivolumab with or without ipilimumab is recruiting 65 patients with a primary endpoint of safety and changes in T-cell infiltration. The estimated study completion date is August 2021.  
Singh H, Madan RA, Dahut WL, et al. Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. J Clin Oncol. 2015;33(suppl 7; abstr 172).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x